Mental Heal
Antipsychotic Treatment for Schizophrenia and Mood Disorders
Company Overview
Snapshot
Founded in October 2012 by Santiago Ini, Mental Heal operates with 1–10 employees. The company has secured funding across one round from two investors, including the Office of the Chief Scientist and Abital, to advance its novel antipsychotic drug development.
Business overview
Mental Heal, operating in the Health Tech & Life Sciences sector, is focused on developing PGW-5, a novel oral antipsychotic drug. This multi-target neuroleptic agent is designed for the treatment of schizophrenia, bipolar disorder, and other mood disorders, potentially impacting cognitive deficits. The company's core technology involves mechanisms related to the brain glutamate NMDA receptor system, neurotrophic factors, and food intake regulating peptides, serving the healthcare and patient markets.
Log in to access full profile ›Company Intelligence Q&A
- What is Mental Heal's primary focus?
- Mental Heal is developing PGW-5, a novel oral antipsychotic drug for the treatment of schizophrenia and bipolar disorder, targeting various mood disorders and cognitive deficits.
- Who founded Mental Heal?
- Mental Heal was founded by Santiago Ini in October 2012.
- What is the primary sector of Mental Heal?
- Mental Heal operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Treatment & Therapeutics.
- Which investors have supported Mental Heal?
- Mental Heal has received funding from the Office of the Chief Scientist and Abital.
- What is the primary sector of Mental Heal?
- Mental Heal operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Treatment & Therapeutics.